Navigation Links
Heritage Pharmaceuticals Inc. Signs Exclusive Development Supply & Distribution Agreement with Dexcel Ltd.
Date:8/5/2014

EATONTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") has signed an Exclusive Development, Supply & Distribution Agreement with Dexcel Ltd. ("Dexcel") for an Extended Release ANDA drug product. Dexcel will be responsible for the development, registration and manufacturing of the product, and Heritage Pharmaceuticals will be responsible for marketing and distribution in the U.S. The product generates generic annual U.S. sales of approximately $60 million, per IMS Health. Financial terms of the agreement were not disclosed.

Jeffrey A. Glazer, Heritage's Vice Chairman and CEO stated, "I am pleased to expand our relationship with Dexcel for high barrier, technology driven pharmaceutical products. This agreement builds upon our platform of pipeline expansion through strategic alliance and will complement our organic product assets as we continue to offer a broad portfolio of value driven medicine to the U.S. consumer."

About Heritage

Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management. Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.

About Dexcel Pharma

Dexcel Pharma is a private international specialty pharmaceutical group, dedicated to the development, manufacturing and commercialization of novel drug formulations and complex generics. Dexcel Pharma has a broad portfolio of branded and generic products, sold in more than 30 countries worldwide. Dexcel Pharma was established in 1968 and is headquartered in Israel.

www.heritagepharma.com

 

Logo - http://photos.prnewswire.com/prnh/20140116/NY47775LOGO


'/>"/>
SOURCE Heritage Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Heritage Provider Network, UCLA and Open mHealth announce the launch of $100,000 mobile apps health prize challenge
2. Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Prize Announced
3. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
4. Heritage Pharma Announces The Return Of Tetracycline HCI Capsules
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries ... technologies. BCC Research reveals in its new report that markets ... should see strong growth due to rising government healthcare spending, increased levels ... Continue Reading ... ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
Breaking Medicine Technology:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... and high-level training standards for healthcare treatment providers who treat the full spectrum ... Presidents Council. , The Presidents Council consists of the leading eating disorder ...
(Date:1/23/2017)... ... , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of ... making new water infrastructure a number one priority. “As we usher in a new ... to become a top priority of our new political change agents.” Kleyne pointed out ...
(Date:1/23/2017)... ... ... METTLER TOLEDO has announced the availability of a new ... . , Crystallization is a common step used during the synthesis ... spend more time developing better intermediate and final crystallization steps. By adopting ...
(Date:1/23/2017)... Aliso Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set ... shaky camera to create dynamic looks in Final Cut Pro X," said Christina Austin - ... movement of up to two layers of text with video footage. ProRandom works by ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):